Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals. Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are ...

Shares of DaVita (DVA) have risen 17.1% in the past three months, outperforming the Zacks Medical - Outpatient and Home Healthcare industry's growth of 13.5% and the broader Zacks Medical sector's return of 2.5%. DVA stock has risen 54.8% year to date, primarily due to rising demand for its dialysis services. The uptrend is likely to continue for the rest of 2024 and beyond as there should be a rising demand for dialysis services due to an expanding patient pool with end-stage renal diseases. Per a report, ...

DaVita HealthCare (DVA) closed at $163.16 in the latest trading session, marking a -0.65% move from the prior day. The stock's performance was behind the S&P 500's daily loss of 0.29%. On the other hand, the Dow registered a loss of 0.25%, and the technology-centric Nasdaq decreased by 0.31%. Coming into today, shares of the kidney dialysis provider had gained 11.27% in the past month. In that same time, the Medical sector gained 1.59%, while the S&P 500 gained 1.57%. The upcoming earnings release of DaVita ...

In the latest trading session, DaVita HealthCare (DVA) closed at $164.22, marking a -0.59% move from the previous day. The stock's change was less than the S&P 500's daily gain of 0.03%. On the other hand, the Dow registered a loss of 0.04%, and the technology-centric Nasdaq increased by 0.2%. Heading into today, shares of the kidney dialysis provider had gained 8.56% over the past month, outpacing the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54% in that time. Analysts and investors alike ...

Kidney care leader provides free health screenings and resources to create awareness around kidney disease and open discussion around health care access DENVER, Sept. 17, 2024 /PRNewswire/ -- DaVita (NYSE: DVA), a leading provider of kidney care services, today announced the launch of its 2024 nationwide community health tour beginning September 24. The DaVita Health Tour is a mobile health screening and chronic disease education program supporting local communities across the country. Now entering its thir ...

When stocks are cruising at or nearing all-time highs, it reflects considerable bullishness with trends where buyers are in control. Stocks making new highs tend to make even higher highs, particularly when analysts' positive earnings estimate revisions are rolling in. That's been precisely the case for Intuitive Surgical (ISRG) , SharkNinja (SN) , and DaVita (DVA) , all of which presently sport a favorable Zacks Rank and are trading near 52-week highs. Let's take a closer look at what's been driving the bu ...

Stock Performance - DaVita HealthCare shares have increased by 5 1% over the past month and hit a new 52-week high of $160 82 [1] - The stock has gained 50 5% since the start of the year compared to the 11 1% move for the Zacks Medical sector and the 17 5% return for the Zacks Medical - Outpatient and Home Healthcare industry [1] Earnings and Revenue - DaVita HealthCare reported EPS of $2 59 versus the consensus estimate of $2 47 in its last earnings report on August 6 2024 and beat the consensus revenue estimate by 0 74% [2] - For the current fiscal year the company is expected to post earnings of $9 99 per share on $12 8 billion in revenues representing a 17 95% change in EPS and a 5 43% change in revenues [3] - For the next fiscal year the company is expected to earn $11 42 per share on $13 31 billion in revenues representing year-over-year changes of 14 37% and 3 97% respectively [3] Valuation Metrics - DaVita HealthCare trades at 15 8X current fiscal year EPS estimates compared to the peer industry average of 24 1X [7] - The stock trades at 9 4X on a trailing cash flow basis versus its peer group's average of 14 2X and has a PEG ratio of 0 9 [7] Zacks Style Scores and Rank - DaVita HealthCare has a Value Score of A Growth Score of C and Momentum Score of D resulting in a VGM Score of B [6] - The company currently has a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates [8] Industry Comparison - The Pennant Group Inc (PNTG) a peer in the industry has a Zacks Rank of 2 (Buy) with a Value Score of C Growth Score of B and Momentum Score of B [9] - PNTG beat the consensus earnings estimate by 14 29% last quarter and is expected to post earnings of $0 92 per share on revenue of $677 7 million for the current fiscal year [10] - Shares of PNTG have gained 6% over the past month and trade at a forward P/E of 36 2X and a P/CF of 42 56X [11] - The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries indicating favorable conditions for both DVA and PNTG [11]

DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18- year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. Dave Maughan, chief operations officer for DaVitaDav ...

DaVita HealthCare (DVA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. The power of a ...

It has been about a month since the last earnings report for DaVita HealthCare (DVA) . Shares have added about 13% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is DaVita HealthCare due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. DaVita Q2 Earnings & Revenues Top Es ...